Basics Amicus Therapeutics, Inc. Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines. IPO Date: May 31, 2007 Sector: Healthcare Industry: Biotech Market Cap: $2.06B Activated in VL: True Average Daily Range Avg Daily Range: $0.24 | 2.68% Avg Daily Range (30 D): $0.16 | 2.08% Avg Daily Range (90 D): $0.13 | 1.54% Institutional Daily Volume Avg Daily Volume: 1.46M Avg Daily Volume (30 D): 3.05M Avg Daily Volume (90 D): 2.25M Trade Size Avg Trade Size (Sh.): 147 Avg Trade Size (Sh.) (30 D): 123 Avg Trade Size (Sh.) (90 D): 110 Institutional Trades Total Inst.Trades: 7,129 Avg Inst. Trade: $2.89M Avg Inst. Trade (30 D): $2.87M Avg Inst. Trade (90 D): $2.57M Avg Inst. Trade Volume: .25M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.56M Avg Closing Trade (30 D): $3.9M Avg Closing Trade (90 D): $3.58M Avg Closing Volume: 311.06K         News Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Feb 10, 2025 @ 12:00 PM Amicus Therapeutics to Announce Full-Year 2024 Fin... Source: N/A Feb 3, 2025 @ 12:00 PM Amicus Therapeutics Announces Presentations and Po... Source: N/A Jan 2, 2025 @ 12:00 PM Amicus Therapeutics to Present at the 43rd Annual ... Source: N/A Nov 15, 2024 @ 11:00 AM Protein Therapeutics Market Size to be Worth USD 5... Source: Transparency Market Research, Inc. Financials   TTM Q3 2024 Q2 2024 Basic EPS $-.34 $-.02 $-.05 Diluted EPS $-.34 $-.02 $-.05 Revenue $ 493.67M $ 141.52M $ 126.67M Gross Profit $ 444.24M $ 128.24M $ 115.41M Net Income / Loss $ -104.69M $ -6.73M $ -15.7M Operating Income / Loss $ 5.21M $ 21.66M $ 14.97M Cost of Revenue $ 49.43M $ 13.28M $ 11.26M Net Cash Flow $ -29.45M $ 24.46M $ -.44M PE Ratio